This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Coming back to post #27, because the follow-up matters more than the original answer.
Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.
Nothing above should be read as advice about what anyone else should do.
Post #31 is right about the mechanism and I think understates the practical bit.
For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.
That is all I can say without guessing.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
I read post #31 twice before replying, because I had assumed the opposite.
On analysis: an amylin analogue and its aggregates are not equally detectable by a standard reversed-phase method, because a large aggregate may not elute at all. Area percent cannot see what stays on the column.
I am confident about the direction and much less about the magnitude.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
Anyone submitting this for independent testing should say in the submission that it is an amylin analogue rather than an incretin. Method selection differs and a default incretin gradient is not necessarily the right one.
If that is already documented somewhere, ignore me and link it.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
Taking post #40 at face value and following it one step further.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
Post #38 and I disagree about the size of the effect, not about the direction.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.
It is worth checking rather than assuming, which costs nothing.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
Somebody will have a better source than mine, and I hope they post it.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
Everything in post #46 holds. The case it does not cover is the one I have.
Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
Not the answer, but possibly the question that gets there.
Where I part company with post #50, and it is a narrow parting.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
Post #50 is the version of this I will quote in future. One addition.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
That is the shape of it. The detail is where I would expect to be corrected.
What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.
Post #53 put the caveat in the right place and I want to underline it.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
I would call that likely rather than established.
Nothing to add on the substance. Thank you for taking the question at face value.
Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.
The arithmetic in post #57 is right; the assumption feeding it is the part to check.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
That holds for the case as described. Change the assumptions and it may not.
Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.
The claim is narrower than it sounds, and deliberately so.